论文部分内容阅读
膀胱肿瘤在泌尿生殖系统中的多发性及其高复发率严重危害了人类的健康,早期的诊断对于肿瘤患者良好的治疗和预后至关重要。膀胱镜检查和尿脱落细胞学检查是目前膀胱癌术前诊断、术后随访的金标准,但前者的侵入性、高费用、可能继发的感染和后者的低敏感性使其应用受到限制。近年来,随着免疫学和蛋白质组学技术的发展,发现膀胱癌特异性核基质蛋白4(BLCA-4)在膀胱肿瘤诊断、监测病情、指导治疗、揭示预后方面显示出高度应用价值,本文现对其研究进展做一总结以期对后续的研究工作做出指导。
Multiple bladder cancer in the urogenital reproductive system and its high recurrence rate seriously endangering human health, early diagnosis of cancer patients with good treatment and prognosis is essential. Cystoscopy and urinary cytology are the gold standard for preoperative diagnosis and postoperative follow-up of bladder cancer. However, their invasiveness, high cost, possible secondary infection and low sensitivity of the latter make their application limited . In recent years, along with the development of immunology and proteomics, bladder cancer-specific nuclear matrix protein 4 (BLCA-4) has been found to have high application value in diagnosing and monitoring bladder cancer, guiding treatment and revealing prognosis. Now a summary of its research in order to guide the follow-up research.